No Data
Wedbush Reiterates Outperform on Edgewise Therapeutics, Maintains $31 Price Target
Wedbush analyst Laura Chico reiterates Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and maintains $31 price target.
Edgewise Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/26/2024 76.84% Wedbush $31 → $31 Reiterates Outperform → Outperform 04/22/2024 82.54% RBC Capital $28 →
Wedbush Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $31
Wedbush analyst Laura Chico maintains $Edgewise Therapeutics(EWTX.US)$ with a buy rating, and adjusts the target price from $26 to $31.According to TipRanks data, the analyst has a success rate of 45.
Express News | Edgewise Therapeutics Inc : Wedbush Adds Stock to Its Best Ideas List
Truist Financial Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating
Truist Financial analyst Srikripa Devarakonda maintains $Edgewise Therapeutics(EWTX.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 46.3% and a total average retur
Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo